• Explore /
  • Poster
  • / A single-arm, open-label, phase Ⅱ study investigating anti-HER2 ADC plus anti-PD-1 antibody in patients with unresectable locally advanced or metastatic BTC with HER2 overexpression.

A single-arm, open-label, phase Ⅱ study investigating anti-HER2 ADC plus anti-PD-1 antibody in patients with unresectable locally advanced or metastatic BTC with HER2 overexpression.

Abstract Poster

Authors

null

Xiaofeng Chen

The First Affiliated Hospital with Nanjing Medical University, Nanjing, China;

Xiaofeng Chen , Fen Guo , Xinyi Zhang , Jinrong Qiu , Tongsen Zheng , Hong Qiu , Yitong Tian , Lanlan Pan , Jiaguang Zhang , Yizhang Chen , Haoyang Shen , Chao Wang

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2023 ASCO Gastrointestinal Cancers Symposium

Session Type

Trials in Progress Poster Session

Session Title

Trials in Progress Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract

Track

Pancreatic Cancer,Hepatobiliary Cancer,Neuroendocrine/Carcinoid,Small Bowel Cancer

Sub Track

Therapeutics

Clinical Trial Registration Number

NCT05540483

Citation

J Clin Oncol 41, 2023 (suppl 4; abstr TPS619)

DOI

10.1200/JCO.2023.41.4_suppl.TPS619

Abstract #

TPS619

Poster Bd #

N8

Abstract Disclosures

Similar Posters

First Author: Sebastian Ochenduszko

First Author: John Ebben

First Author: Fang Yuan

First Author: Marilyn Fontaine